You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖-B(02315.HK)2024年度業績亮眼:收入大增36.8%,全球藥企合作加速
格隆匯 03-26 16:42

格隆匯3月26日丨百奧賽圖-B(02315.HK)公佈年度業績,2024年度,集團實現收入人民幣9.805億元,繼續保持快速增長,較上年同期增長約36.8%;淨利潤為人民幣3350萬元,同比實現扭虧為盈;經營活動所得現金淨流入為人民幣2.112億元。2024年度,對於公司是具有里程碑意義的一年,在半年度經營活動現金流轉正的基礎上,全年淨利潤實現扭虧為盈。扭虧為盈目標的順利完成標誌着集團戰略調整以及運營優化的顯著成效,集團將可以依靠自身現金生產能力支持未來的發展。

2024年度,抗體發現業務獲得更多海外客户的認可,全球前10大藥企中的7家成為公司抗體發現業務的客户,對外轉讓的抗體分子數量快速增加,銷售收入快速增長的同時,毛利率保持在較高水平。抗體發現業務實現收入人民幣3.178億元,較上年同期增長80.7%,佔公司總收入32.4%。截至2024年12月31日,集團累計簽署約200項藥物合作開發╱授權╱轉讓協議。其中,2024年度新增簽署約100項,較去年同期增長約70%。

2024年度,基於初步成型的全球化網絡體系,特別是配備了先進實驗室以及高標準動房的美國波士頓運營設施,模式動物業務和抗體發現業務繼續保持快速增長,尤其是海外業務收入貢獻比例進一步提高,收入增長的同時毛利依然保持穩定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account